Press releases

Month Year

Email alerts

Mar 25, 2012

Medtronic Symplicity™ Renal Denervation System Demonstrates Significant and Sustained Blood Pressure Reduction out to Three Years

Data from Two Clinical Trials Presented at the 61st Annual Scientific Session of the American College of Cardiology Show Consistent Effectiveness and Safety Up to Three Years

MINNEAPOLIS & CHICAGO--(BUSINESS WIRE)--Mar. 25, 2012-- Medtronic, Inc. (NYSE:MDT), announced that the Symplicity™ renal denervation system provides safe, significant and sustained blood...
Mar 24, 2012

Data Presented at ACC Reinforce Positive Clinical Outcomes for Patients Receiving Medtronic’s CoreValve® System

MINNEAPOLIS--(BUSINESS WIRE)--Mar. 24, 2012-- Medtronic, Inc. (NYSE: MDT) today announced results from its largest international, prospective, single-arm clinical trial evaluating the Medtronic...
Mar 24, 2012

Medtronic Resolute® Drug-Eluting Stent Delivers Durable Clinical Outcomes Through Two Years in Major Studies

Recently FDA-Approved, Novel Heart Device Shows Consistently Low Event Rates Across Broad Spectrum of Coronary Artery Disease Patients, Including Those with Diabetes

CHICAGO--(BUSINESS WIRE)--Mar. 24, 2012-- According to new clinical data presented today at ACC.12 –– the 61st Annual Scientific Session & Expo of the American College of Cardiology (ACC)...
Mar 15, 2012

Medtronic Receives Health Canada License for Deep Brain Stimulation Therapy in Refractory Epilepsy Patients

Another Medtronic First in Neuromodulation in Canada

BRAMPTON, Ontario & MINNEAPOLIS--(BUSINESS WIRE)--Mar. 15, 2012-- Medtronic, Inc. (NYSE: MDT) today announced that it has received from Health Canada a license for Medtronic Deep Brain Stimulation...
Mar 14, 2012

Medtronic Announces Public Offering of Senior Notes

MINNEAPOLIS--(BUSINESS WIRE)--Mar. 14, 2012-- Medtronic, Inc. (NYSE:MDT) today announced a registered offering of $675 million of its 3.125% Senior Notes due 2022 and $400 million of its 4.50%...

Show per page